Abivax prices upsized $800M ADS offering to fund obefazimod launch
Abivax has priced an upsized public offering of American Depositary Shares at $125.00 per ADS, raising approximately $800 million (around €702 million) in gross proceeds before underwriting commissions. The offering, which was increased from a previously announced $600 million, was described as oversubscribed and priced at a 2.39% premium to the three-day volume-weighted average price of Abivax's ordinary shares on Euronext Paris.
The company issued 6.4 million ADSs, each representing one ordinary share, with the transaction expected to close on 6 July 2026. Underwriters have also been granted an option to purchase up to an additional 960,000 ADSs, representing 15% of the offering size, exercisable on or before the same date. Full exercise would lift gross proceeds to approximately $920 million (around €807 million).
Use of proceeds and runway
Abivax said it intends to use the net proceeds primarily to fund potential commercialisation of its lead drug candidate, obefazimod (ABX464), in the United States, alongside continued clinical development costs for its ulcerative colitis and Crohn's disease programmes. Any remaining funds will be allocated to general corporate purposes.
The company reported cash, cash equivalents and short-term investments of €491.6 million as of 31 March 2026, which had been sufficient to sustain operations into the fourth quarter of 2027 under its previous operating assumptions. Combined with the new proceeds, the extended runway into the second quarter of 2029 gives Abivax meaningful headroom to pursue a potential approval and commercial launch of obefazimod. The offering will dilute existing shareholders by approximately 8.0% on a non-diluted basis, rising to 9.2% if the underwriters' option is exercised in full.
Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities are acting as joint bookrunning managers. LifeSci Capital is serving as passive bookrunning manager and Van Lanschot Kempen as lead manager.
Market context and competitive backdrop
Obefazimod is currently in Phase 3 trials for moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease with a substantial and growing global patient population. The IBD treatment market is highly competitive, with established biologic and small-molecule therapies from major players already on the market, including anti-TNF agents, anti-integrin antibodies and JAK inhibitors. More recently, selective agents targeting the IL-23 pathway have further crowded the approved landscape.
Abivax is positioning obefazimod as an orally administered candidate that modulates the immune response through a distinct mechanism. If approved, it would enter a market where payer and prescriber expectations around efficacy, safety and convenience are already high. The scale of this capital raise signals that Abivax is planning to build or contract a meaningful commercial infrastructure in the US rather than rely on a partnership for the initial launch, though no commercial collaborator has been named.
The size and oversubscription of the offering reflects continued investor appetite for late-stage inflammatory disease assets, even as broader biotech valuations have remained sensitive to interest rate conditions. For Abivax, the key near-term milestones will be Phase 3 readout timing, any FDA pre-NDA meeting outcomes, and whether the underwriters exercise their greenshoe option in full.